FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Re	esponses)															
Name and Address of Reporting Person* Oliviero James F III				2. Issuer Name and Ticker or Trading Symbol Checkpoint Therapeutics, Inc. [CKPT]								5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
2 GANSEVOORT ST, 9TH FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 01/06/2021							ar)		X Officer (give title below) Other (specify below) CEO, President and Director					
(Street) NEW YORK, NY 10014				4. If Amendment, Date Original Filed(Month/Day/Year)							Year)		6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu							rities A	Acquir	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year		Code		on (A	4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Benefic Reporte	ount of Securities cially Owned Following ed Transaction(s) 3 and 4)		Ownership Form: Direct (D)	Beneficial Ownership		
						Code		V	Amount	(A) or (D)	Price			(I	or Indirect (I) (Instr. 4)	(Instr. 4)	
COMMON S (RESTRICTE			01/06/2021					A	5. (1	39,000 1	A	\$ 0	3,272,	000 (2)		D	
			Table II - D					th quired,	e form	displa	ys a c r Bene	urren ficiall	tly valid	uired to res	•		
(Instr. 3) Price	version xercise e of vative	3. Transaction Date (Month/Day/Y	3A. Deemed Execution Date	4. Transaction Code		ttion 1 () () () () () () () () () (5.		6. Date Exercisable and Expiration Date (Month/Day/Year)		ole ate r)	7. Tit Amo Unde Secui (Instr 4)	tle and unt of critics : 3 and Amount or Number	f g Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form o Derivat Securit Direct (or India	Beneficia Ownershi (Instr. 4) D) ect
				C	Code	V	(A)	(D) E	xercisa	ble Date	;	Title	of Shares				
Reportin	ıg O	wners															

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Oliviero James F III 2 GANSEVOORT ST, 9TH FLOOR NEW YORK, NY 10014	X		CEO, President and Director				

Signatures

/s/ James F. Oliviero, III	01/08/2021	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of restricted stock vest as follows: one-fourth on January 6, 2022, one-fourth on January 6, 2023, one-fourth on January 6, 2024 and one-fourth on January 6, 2025.
- (2) Includes shares of restricted Common Stock, which vest over various time periods.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.